Crossmark

Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding

Crossref DOI link: https://doi.org/10.1186/s13023-020-01453-1

Published Online: 2020-07-13

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Beckman, Joan D.

Li, Quefeng

Hester, Samuel T.

Leitner, Ofri

Smith, Karen L.

Kasthuri, Raj S. http://orcid.org/0000-0001-6672-3082
License Information

Text and Data Mining valid from 2020-07-13

Version of Record valid from 2020-07-13
More Information

Article History

Received: 9 April 2020

Accepted: 29 June 2020

First Online: 13 July 2020

Ethics approval and consent to participate

: The University of North Carolina IRB approval was obtained to retrospectively review the medical records of adult patients with possible HHT who were evaluated at UNC HHT Clinic between January 1, 2009 to February 28, 2015.

: Not applicable.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below